Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

New study suggests the combination of  targeting  the MEK/ERK and PI3K/mTOR pathways has antitumor activity and could be a therapeutic option in the treatment of NRAS mutant melanoma, for which there are currently no effective therapies.